GENECHOC: Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy
Study Details
Study Description
Brief Summary
The aim of this project is to identify common genetic polymorphisms associated with the occurrence of rhythmic events in patients with severe cardiomyopathy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Appropriate treatment Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation |
Genetic: Identification of genetic polymorphisms
|
| No event Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study. |
Genetic: Identification of genetic polymorphisms
|
Outcome Measures
Primary Outcome Measures
- Prevalence of polymorphisms pre-selected candidates (or by direct sequencing by High Resolution Melting). [4 years]
- Identification of polymorphisms frequent (> 5% in the general population) by association study ( "Genome Wide Association Study '(GWAS)) using genotyping technology broadband Axiom (Affymetrix). [4 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients implanted for primary prevention, an implantable cardioverter defibrillator (ICD) single or double room, for severe cardiomyopathy (EF <35%)
-
Patients with ischemic cardiomyopathy or idiopathic dilated cardiomyopathy.- "Appropriate treatment" group: patients who had a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
-
Group "no event" patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive proper treatment during the follow up period of the study
Exclusion Criteria:
-
Patients implanted with an ICD for primary prevention in the context of a family hereditary disease (long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy, ventricular tachycardia catecholergic right ventricular dysplasia ...).
-
Patients with left ventricular function greater than 35%.
-
Patients implanted with a defibrillator function resynchronization.
-
Patients minors, adults under guardianship and protected persons are eligible under this project.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Angers | Angers | France | ||
| 2 | CHU Bordeaux | Bordeaux | France | ||
| 3 | CHU Brest | Brest | France | ||
| 4 | CHU Clermont-Ferrand. | Clermont-Ferrand | France | ||
| 5 | CHU Dijon | Dijon | France | ||
| 6 | CHU Grenoble | Grenoble | France | ||
| 7 | CH La Rochelle | La Rochelle | France | ||
| 8 | CHRU Lille | Lille | France | ||
| 9 | CHU Lyon | Lyon | France | ||
| 10 | CHU Marseille | Marseille | France | ||
| 11 | CHU Montpellier | Montpellier | France | ||
| 12 | CHU Nancy | Nancy | France | ||
| 13 | CHU Nantes | Nantes | France | ||
| 14 | CHU Rennes | Rennes | France | ||
| 15 | CHU Rouen | Rouen | France | ||
| 16 | CHRU Strasbourg | Strasbourg | France | ||
| 17 | CHU Toulouse | Toulouse | France | ||
| 18 | CHU Tours | Tours | France |
Sponsors and Collaborators
- Nantes University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PROG/10/77